GlassScriptPhysician profile
Peter P Michalak
NPI 1104321777
$2,200.73
in general payments reported to CMS, 2019-2025
24 companies · $760 in 2025
The $760 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $422 · 2023: $431 · 2024: $587 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $618.04 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $317.25 | 2022-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $165.48 | 2022-2025 | |
| Glaxosmithkline, LLC. | $136.72 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $130.30 | 2022-2025 | |
| Novo Nordisk INC | $98.49 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $95.85 | 2022-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $69.54 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $65.01 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Nevro Corp. | $60.69 | 2023-2024 | Senza |
| Sanofi Pasteur INC. | $58.59 | 2023-2025 | |
| Exact Sciences Corporation | $58.21 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $49.38 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $36.80 | 2023-2024 | Xarelto |
| Amneal Pharmaceuticals LLC | $34.17 | 2024-2025 | Unithroid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $32.46 | 2022-2023 | |
| Boston Scientific Corporation | $29.55 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.67 | 2022-2023 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.41 | 2025 | Caplyta |
| Almatica Pharma LLC | $21.89 | 2023 | Loreev Xr |
| Astellas Pharma US INC | $20.31 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $19.16 | 2023 | |
| Sanofi-Aventis U.S. LLC | $17.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.15 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Michalak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.